Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver
{{output}}
Combination platinum-based therapy has been the standard of care for the treatment of advanced non-small-cell lung cancer (NSCLC). Immunotherapy has emerged and demonstrated to show benefit in the treatment of patients with advanced NSCLC. In this review, we d... ...
